RxDoctor Payments Data

Varadendra Panchamukhi, MD

Interventional Cardiology · McKinney, TXNPI 1447332457

Payments from drug & device makers

$3,349in general payments, 2019–2025

Across 136 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$299
  • Abbott$278
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$276
  • Cardiovascular Systems Inc.$270
  • Novartis$220
  • Merck$209
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,349 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$237,430
Medicare patients
807
Services billed
2,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$252,376
BrilintaTicagrelor31$28,544
XareltoRivaroxaban21$27,195
EntrestoSacubitril/Valsartan22$24,569
Amiodarone Hcl68$2,527
Metoprolol Succinate152$1,767
Nifedipine ErNifedipine39$1,612
ClopidogrelClopidogrel Bisulfate140$1,596
Losartan Potassium134$1,313
Atorvastatin Calcium164$1,154
Amlodipine Besylate109$928
Carvedilol118$823
Lisinopril52$749
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$526
Felodipine ErFelodipine12$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$299$252,376243 claims
AstraZenecaBrilinta$25$28,54431 claims
Johnson & JohnsonXarelto$37$27,19521 claims
NovartisEntresto$220$24,56922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →